Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | EGFR | P00533 | 20/20 | 0.89 |
| ▸ | MLNR | O43193 | 1/20 | 0.89 |
| ▸ | KDM1A | O60341 | 1/20 | 0.89 |
| ▸ | ABCB11 | O95342 | 1/20 | 0.89 |
| ▸ | ERBB2 | P04626 | 1/20 | 0.89 |
| ▸ | INSR | P06213 | 1/20 | 0.89 |
| ▸ | CHRM2 | P08172 | 1/20 | 0.89 |
| ▸ | HTR1A | P08908 | 1/20 | 0.89 |
| ▸ | ADORA3 | P0DMS8 | 1/20 | 0.89 |
| ▸ | DRD2 | P14416 | 1/20 | 0.89 |
| ▸ | NQO2 | P16083 | 1/20 | 0.89 |
| ▸ | ADRA2C | P18825 | 1/20 | 0.89 |
| ▸ | DRD1 | P21728 | 1/20 | 0.89 |
| ▸ | ERBB3 | P21860 | 1/20 | 0.89 |
| ▸ | SLC6A2 | P23975 | 1/20 | 0.89 |
| ▸ | HTR2A | P28223 | 1/20 | 0.89 |
| ▸ | HTR2C | P28335 | 1/20 | 0.89 |
| ▸ | ADORA2A | P29274 | 1/20 | 0.89 |
| ▸ | SLC6A4 | P31645 | 1/20 | 0.89 |
| ▸ | CCKAR | P32238 | 1/20 | 0.89 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL20365492 | 0.96 | EGFR (0.89) | EGFRMLNRKDM1AABCB11ERBB2 | |
| SCHEMBL19336988 | 0.94 | EGFR (0.89) | EGFRMLNRKDM1AABCB11ERBB2 | |
| Osimertinib SCHEMBL29350904 | 0.94 | EGFR (1.00) | EGFRMLNRKDM1AABCB11ERBB2 | |
| Osimertinib SCHEMBL29378405 | 0.94 | EGFR (1.00) | EGFRMLNRKDM1AABCB11ERBB2 | |
| Osimertinib SCHEMBL14660911 | 0.94 | EGFR (1.00) | EGFRMLNRKDM1AABCB11ERBB2 | |
| SCHEMBL19336896 | 0.94 | EGFR (0.88) | EGFRMLNRKDM1AABCB11ERBB2 | |
| SCHEMBL19337057 | 0.94 | EGFR (0.88) | EGFRMLNRKDM1AABCB11ERBB2 | |
| SCHEMBL19254679 | 0.94 | EGFR (0.88) | EGFRMLNRKDM1AABCB11ERBB2 | |
| SCHEMBL28841203 | 0.94 | EGFR (0.88) | EGFRMLNRKDM1AABCB11ERBB2 | |
| SCHEMBL20365493 | 0.93 | EGFR (0.86) | EGFRMLNRKDM1AABCB11ERBB2 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20180193470-A1 | EGFR PROTEOLYSIS TARGETING CHIMERIC MOLECULES AND ASSOCIATED METHODS OF USE | ARVINAS OPERATIONS, INC. | 2018-07-12 | — | — | US | disclosed |
| WO-2017134051-A1 | IMPROVED PROCESS FOR THE PREPARATION OF OSIMERTINIB (AZD9291) OR A SALT THEREOF, AND \"AZD9291 ANILINE\" OR A SALT THEREOF | ASTRAZENECA AB (SE) | 2017-08-10 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20180193470-A1 | EGFR PROTEOLYSIS TARGETING CHIMERIC MOLECULES AND ASSOCIATED METHODS OF USE | EGFR, ERBB2, ERBB3 | EGFR 1/4885MLNR 1381/4885KDM1A 2996/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.